Revenue: As of FY2025 Q3, the actual value is USD 6.829 M, missing the estimate of USD 8.521 M.EPS: As of FY2025 Q3, the actual value is USD -0.12, missing the estimate of USD -0.102.EBIT: As of FY2025 Q3, the actual value is USD -15.88 M.<h3>Segment Revenue</h3><ul><li>Total Revenue: $6.8 million for the three months ended September 30, 2025, a decrease of 16% compared to $8.2 million for the same period in 2024.</li><li>Core Revenue: $6.4 million for the three months ended September 30, 2025, a decrease of 21% compared to $8.1 million for the same period in 2024.</li><li>Non-Core Revenue (SPL Program-related): $0.4 million for the three months ended September 30, 2025, an increase of 1,663% compared to $24,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $12.4 million for the three months ended September 30, 2025, compared to $11.6 million for the same period in 2024.</li><li>Gross Profit: $5.2 million for the three months ended September 30, 2025, a decrease of 16% compared to $6.2 million for the same period in 2024.</li><li>Gross Margin: 77% for the three months ended September 30, 2025, compared to 76% for the same period in 2024.</li><li>Operating Loss: $14.1 million for the three months ended September 30, 2025, compared to $14.1 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $31.7 million for the nine months ended September 30, 2025, compared to $19.8 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $16.3 million for the nine months ended September 30, 2025, compared to $8.6 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $0.6 million for the nine months ended September 30, 2025, compared to $1.6 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Restructuring Expense: $3.1 million incurred during the three months ended September 30, 2025, due to a workforce reduction plan.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: MaxCyte, Inc. plans to continue investing in research and development to support customers, develop new uses for existing technology, and enhance product offerings. The company expects total revenue to increase over time as customer programs advance and markets grow, resulting in additional instrument sales and license and PA sales.</li><li>Non-Core Business: The company anticipates variability in program-related revenue to moderate as the volume of SPL partnerships and associated milestones grows and matures.</li></ul>

MaxCyte | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 6.829 M